Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.71 |
| ▸ | STAT6 | P42226 | 5/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 4/20 | 0.47 |
| ▸ | JAK3 | P52333 | 4/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737343 | 0.83 | SYK (1.00) | SYK | |
| SCHEMBL912928 | 0.76 | EGFR (0.59) | SYKJAK2JAK3MAPK8MAPK9 | |
| SCHEMBL763172 | 0.76 | SYK (0.71) | SYKSTAT6JAK3 | |
| SCHEMBL1353614 | 0.74 | SYK (1.00) | SYK | |
| SCHEMBL27371396 | 0.73 | MAPK8 (0.58) | SYKSTAT6JAK3MAPK8MAPK9 | |
| SCHEMBL19675838 | 0.73 | SYK (0.60) | SYKSTAT6JAK2JAK1JAK3 | |
| SCHEMBL2627049 | 0.72 | SYK (0.53) | SYKJAK2JAK1JAK3MAPK8 | |
| SCHEMBL736617 | 0.72 | SYK (1.00) | SYK | |
| SCHEMBL21554060 | 0.71 | SYK (0.78) | SYKSTAT6JAK2JAK1JAK3 | |
| SCHEMBL914664 | 0.71 | ULK1 (0.61) | SYKSTAT6TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885STAT6 319/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.